点击小程序查看报告原文 Abstract 摘要 通过"跨国公司成长启示录"，我们希望总结跨国龙头的成功经验，为中国企业的全球化发展提供参考。第一篇主要探讨跨国公司的发展历程及其在全球经 济中的重要性， 本篇报告重点 关注 美国、欧洲、日本三个区域跨国公司的发展情况， 将从企业为何出海、数说跨国公司、典型行业（选取美国科技、欧 洲医药、日本汽车）分别展开。 基于对美欧日跨国公司的比较，我们发现虽然三大经济体企业出海的时代背景各异，但是 底层逻辑上呈现高度一致性，即突破增长天花板、规避贸易壁 垒、全球范围成本套利。 与此同时，不同经济体依托各自资源禀赋、产业根基、制度框架，全球化历程走出不同的发展路径。我们总结如下： 美国：聚焦高附加值，技术引领全球。 1）从出海必要性而言，美国反垄断监管限制大企业的国内发展空间，是企业海外扩张的重要原因。另外，追求生 产要素最优配置是跨国公司构筑全球竞争力的基础逻辑，近年来提高供应链安全成为海外投资布局的重要考量。2）美国凭借全球领先的研发创新体系、 完善的知识产权保护制度、成熟的科技成果转化机制，在高附加值领域构筑技术护城河，科技行业最为典型。我们认为 ①建立领先优势并掌控全 ...

Key Takeaways Bayer's finerenone met the primary endpoint in the phase III FIND-CKD study in non-diabetic CKD patients.Finerenone slowed kidney function decline vs placebo, reinforcing benefits beyond diabetic CKD.Bayer plans regulatory filings to expand Kerendia's indication following strong late-stage results.Bayer (BAYRY) announced that finerenone achieved the primary endpoint in the late-stage FIND-CKD study, marking a key milestone in expanding its use to patients with non-diabetic chronic kidney disea ...

Core Insights - Bayer Crop Science Canada has launched the 2026 Bayer Crop Science Opportunity Scholarship, offering 12 scholarships valued at $5,000 CAD each to students entering post-secondary education in agriculture, food science, or culinary arts, with a preference for applicants of Canadian Indigenous heritage [1][2][4] Group 1: Scholarship Program Details - The scholarship aims to empower students to explore educational opportunities that contribute to an innovative farming and food system in Canada [2] - Eligibility requires candidates to be studying at recognized educational institutions in programs related to agriculture, food science, or culinary arts that are at least two years in duration [6] - The application deadline for the scholarship is May 14, 2026, and detailed guidelines are available on the Bayer Crop Science Canada website [3] Group 2: Company Overview - Bayer is a global enterprise focused on health care and nutrition, with a mission of "Health for all, Hunger for none," aiming to address challenges posed by a growing global population [5] - In fiscal 2025, Bayer employed approximately 88,000 people and reported sales of €45.6 billion, with R&D expenses amounting to €5.8 billion [5]

Bayer AG (OTCMKTS:BAYRY) is among the best German stocks to buy according to analysts. On March 5, Bayer AG (OTCMKTS:BAYRY) announced that the FDA has cleared its MEDRAD MRXperion MR injector system for expanded application. That means this contrast injector system can now be used across a broader range of MRI scanners, including those with magnetic fields up to 7 Tesla. Bayer AG (BAYRY) Receives FDA Approval For Expanded MR Injector Application Bayer’s MEDRAD MRXperion is used in MRI diagnostic procedur ...

Core Insights - Bayer Co.Lab has welcomed two biotech startups, Arbele and Mingcheng Bio, to its global co-creation platform, aiming to accelerate innovative drug development and provide breakthrough treatments for patients [1][3] - The inclusion of these companies highlights China's significant potential as a source of innovation in the biopharmaceutical sector, with Bayer Co.Lab having attracted a total of 12 local startups within just over a year [1][6] Group 1: Arbele - Arbele is focused on developing precision therapies for solid tumors, particularly targeting the CDH17 marker, and has advanced its core project ARB202 into the dose-expansion phase after completing Phase I studies [4] - The company aims to leverage Bayer's global resources to expedite its research and development processes, addressing urgent medical needs in cancer treatment [3][4] Group 2: Mingcheng Bio - Mingcheng Bio specializes in GPCR-related technology services and has developed an integrated early drug discovery platform that addresses challenges in GPCR drug development [5] - The company has established a library of over 170 active GPCR proteins and has completed numerous cryo-electron microscopy structural analyses, enhancing its capabilities in antibody discovery and functional screening [5] Group 3: Bayer Co.Lab Overview - Bayer Co.Lab officially launched in China in September 2024, and with the addition of Arbele and Mingcheng Bio, it has formed a diverse biopharmaceutical innovation cluster that includes small molecules, nucleic acid drugs, and AI drug discovery [6] - The platform aims to foster open collaboration within the biotechnology ecosystem, facilitating the transformation of innovative results into impactful healthcare solutions [6]

Core Viewpoint - The article emphasizes Bayer's long-term commitment to the Chinese market, highlighting its strategic investments and innovations that align with China's economic policies and development goals [1][2][3]. Group 1: Bayer's Historical Commitment to China - Bayer has been rooted in China for 144 years, marking its presence as one of the earliest multinational companies in the country [2]. - The establishment of Bayer China Limited in 1994 signified a systematic and comprehensive approach to its operations in China, evolving from trade to a full ecosystem of manufacturing, research, and innovation [2]. - Over the past three decades, Bayer has continuously increased its investment in China, including modern pharmaceutical production facilities and research centers [3]. Group 2: Recent Developments and Investments - In 2024, Bayer will launch two major research and innovation platforms in Shanghai, and by 2025, it will open a manufacturing center for crop protection products in Hangzhou with an investment exceeding 300 million RMB [3]. - As of March 2026, Bayer is expected to employ around 7,000 people in China and has established multiple supply and research centers [3]. Group 3: Alignment with Chinese Policies - Bayer's mission of "shared health and eliminating hunger" aligns with China's emphasis on biomedicine as a new pillar industry and its initiatives for rural revitalization and agricultural modernization [6][8]. - The company has successfully launched 19 innovative prescription drugs in China, reflecting its ability to synchronize with the country's drug approval processes [6]. Group 4: Innovation and Collaboration - Bayer is transitioning from merely introducing global innovations to enabling Chinese innovations to reach the world, exemplified by its partnerships with top Chinese universities and local biotech firms [11][12]. - The Bayer Co.Lab in China supports startups by providing funding, technical empowerment, and global networking opportunities, facilitating their entry into international markets [12]. Group 5: Future Outlook - Bayer aims to continue collaborating with Chinese innovation partners to build a community that benefits both China and the global market, contributing to sustainable development and national strategic goals [12].

Core Insights - Bayer AG has received preliminary approval for a proposed class action settlement regarding Roundup litigation, which aims to resolve claims that Roundup caused non-Hodgkin lymphoma [1][10] - The settlement framework is part of Bayer's strategy to manage its long-standing Roundup litigation exposure, which has negatively impacted investor sentiment [3] - A fairness hearing is scheduled for July 9, 2026, to determine final approval of the settlement [2] Legal Developments - The Missouri Circuit Court judge's approval allows for a 90-day opt-out and objection period for potential class members, ending on June 4, 2026 [2] - The U.S. Supreme Court is reviewing the Durnell case, which may influence state-level failure-to-warn claims related to Roundup [4] - Bayer has set aside $11.3 billion (€9.6 billion) for glyphosate litigation as of December 31, 2025, reflecting the significant costs incurred from ongoing lawsuits [7][10] Company Performance - Bayer's shares have increased by 64.1% over the past year, significantly outperforming the industry average gain of 8.6% [9] - Despite missing sales targets in the fourth quarter, Bayer's overall performance in 2025 was strong, driven by new products in the Pharmaceutical division [11] - The FDA has granted approvals for several new drugs, including elinzanetant and Hyrnuo, which are expected to enhance sales [12][13] Future Outlook - Bayer anticipates that litigation impacts will continue to affect its cash position in 2026 [14] - The company is focused on expanding its product portfolio and addressing legal liabilities to improve investor confidence and financial stability [3][11]

Bill Anderson, Bayer's chief executive, updates investors on his turnaround plan for the German drugs and chemicals firm following its disastrous Monsanto acquisition. https://t.co/eM3VDWTYIh ...

Core Point - A Missouri state court judge has approved a proposed $7.25 billion settlement to address thousands of lawsuits alleging that Bayer's Roundup weedkiller is linked to cancer [1] Group 1 - The settlement aims to resolve numerous legal claims against Bayer regarding the health risks associated with Roundup [1] - The proposed amount of the settlement is $7.25 billion, indicating a significant financial impact on Bayer [1]

Core Insights - Bayer AG reported fourth-quarter 2025 core earnings of 18 cents per American Depositary Receipt (ADR), matching the Zacks Consensus Estimate, but down 41% year over year from 28 cents per ADR in the previous year [1][2] - Total sales for the quarter were $13.31 billion, a decrease of 2.5% on a reported basis, falling short of the Zacks Consensus Estimate of $13.41 billion [2][8] - Bayer's shares have increased by 66.4% over the past year, significantly outperforming the industry average gain of 9.1% [2] Financial Performance - Bayer's revenues for 2025 totaled $51.5 billion, missing the Zacks Consensus Estimate of $53.2 billion, and reflecting a 2.2% decline from 2024 [15] - Core earnings per ADR for 2025 were $1.39, also below the Zacks Consensus Estimate of $1.41 [15] Segment Performance - Crop Science sales rose 6.3% to €5.4 billion, with Corn Seed & Traits sales increasing by 28.5% due to strong performance in North America and Latin America [5] - The Pharmaceuticals segment saw a 1.7% increase in sales to €4.5 billion, driven by strong sales of Nubeqa and Kerendia, although offset by declines in Xarelto and Eylea [9][12] - Consumer Health sales decreased by 4.6% to €1.5 billion, primarily due to a decline in the Allergy & Cold business [14] Future Guidance - For 2026, Bayer expects sales in the range of €45-€47 billion, with flat to modest growth anticipated across all divisions [16] - Core EPS is projected to be between €4.30 and €4.80 [16] Product Developments - New products like Nubeqa and Kerendia continue to show strong momentum, helping to mitigate declines in other areas [18] - The launch of Eylea 8 mg has partially offset declines in Eylea sales, which faced pressure from generics [10][18] - Recent FDA approvals for drugs like elinzanetant and Hyrnuo are expected to further enhance sales [19][20] Legal and Regulatory Updates - Bayer has reached a proposed class settlement regarding the Roundup litigation, which has positively impacted investor sentiment [21][22] - The company anticipates that litigation impacts may burden its cash position in 2026 [22]